Barclays PLC Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Barclays PLC lifted its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 165.5% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 158,491 shares of the company’s stock after acquiring an additional 98,791 shares during the quarter. Barclays PLC owned 0.23% of Replimune Group worth $1,738,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in Replimune Group by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 180,226 shares of the company’s stock worth $1,622,000 after purchasing an additional 17,471 shares during the period. Rhumbline Advisers increased its holdings in shares of Replimune Group by 7.2% in the second quarter. Rhumbline Advisers now owns 84,923 shares of the company’s stock worth $764,000 after buying an additional 5,732 shares during the period. TD Asset Management Inc lifted its stake in shares of Replimune Group by 4.6% in the 2nd quarter. TD Asset Management Inc now owns 249,940 shares of the company’s stock valued at $2,249,000 after acquiring an additional 11,094 shares during the last quarter. Arizona State Retirement System bought a new stake in shares of Replimune Group in the 2nd quarter valued at about $108,000. Finally, Los Angeles Capital Management LLC boosted its holdings in Replimune Group by 8.1% during the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after acquiring an additional 5,410 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. JPMorgan Chase & Co. lifted their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Jefferies Financial Group lifted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research report on Friday, November 22nd. Finally, BMO Capital Markets raised their price target on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Replimune Group has a consensus rating of “Buy” and a consensus price target of $17.29.

Replimune Group Stock Down 4.1 %

Shares of Replimune Group stock opened at $11.06 on Friday. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a market cap of $756.69 million, a P/E ratio of -3.63 and a beta of 1.28. The company’s fifty day simple moving average is $12.39 and its two-hundred day simple moving average is $11.13.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Research analysts anticipate that Replimune Group, Inc. will post -2.91 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.